Recombinant
RabMAb

Anti-STAT1 alpha antibody [EPYR2154] (HRP) (ab193891)

Overview

  • Product name
    Anti-STAT1 alpha antibody [EPYR2154] (HRP)
    See all STAT1 alpha primary antibodies
  • Description
    Rabbit monoclonal [EPYR2154] to STAT1 alpha (HRP)
  • Host species
    Rabbit
  • Conjugation
    HRP
  • Tested applications
    Suitable for: WBmore details
  • Species reactivity
    Reacts with: Mouse, Human
  • Immunogen

    A synthetic peptide corresponding to residues within Human STAT1

  • Positive control
    • WB: HeLa, HEK293, NIH-3T3 and A431 cell lysates.
  • General notes

     

     

    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

Properties

Applications

Our Abpromise guarantee covers the use of ab193891 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB
  • Application notes
    Flow Cyt: 1/50.
    IP: 1/50.
    WB: 1/1000 - 1/2000. Predicted molecular weight: 87 kDa.

    Is unsuitable for ICC or IHC-P.

    Not yet tested in other applications.
    Optimal dilutions/concentrations should be determined by the end user.
  • Target

    • Function
      Signal transducer and activator of transcription that mediates signaling by interferons (IFNs). Following type I IFN (IFN-alpha and IFN-beta) binding to cell surface receptors, Jak kinases (TYK2 and JAK1) are activated, leading to tyrosine phosphorylation of STAT1 and STAT2. The phosphorylated STATs dimerize, associate with ISGF3G/IRF-9 to form a complex termed ISGF3 transcription factor, that enters the nucleus. ISGF3 binds to the IFN stimulated response element (ISRE) to activate the transcription of interferon stimulated genes, which drive the cell in an antiviral state. In response to type II IFN (IFN-gamma), STAT1 is tyrosine- and serine-phosphorylated. It then forms a homodimer termed IFN-gamma-activated factor (GAF), migrates into the nucleus and binds to the IFN gamma activated sequence (GAS) to drive the expression of the target genes, inducing a cellular antiviral state.
    • Involvement in disease
      Note=STAT1 deficiency results in impaired immune response leading to severe mycobacterial and viral diseases. In the case of complete deficiency, patients can die of viral disease.
      Defects in STAT1 are a cause of mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]; also known as familial disseminated atypical mycobacterial infection. This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance.
    • Sequence similarities
      Belongs to the transcription factor STAT family.
      Contains 1 SH2 domain.
    • Post-translational
      modifications
      Phosphorylated on tyrosine and serine residues in response to IFN-alpha, IFN-gamma, PDGF and EGF. Phosphorylation on Tyr-701 (lacking in beta form) by JAK promotes dimerization and subsequent translocation to the nucleus. Phosphorylation on Ser-727 by several kinases including MAPK14, ERK1/2 and CAMKII on IFN-gamma stimulation, regulates STAT1 transcriptional activity. Phosphorylation on Ser-727 promotes sumoylation though increasing interaction with PIAS. Phosphorylation on Ser-727 by PKCdelta induces apoptosis in response to DNA-damaging agents.
      Sumoylated by SUMO1, SUMO2 and SUMO3. Sumoylation is enhanced by IFN-gamma-induced phosphorylation on Ser-727, and by interaction with PIAS proteins. Enhances the transactivation activity.
      ISGylated.
    • Cellular localization
      Cytoplasm. Nucleus. Translocated into the nucleus in response to IFN-gamma-induced tyrosine phosphorylation and dimerization.
    • Information by UniProt
    • Database links
    • Alternative names
      • CANDF7 antibody
      • DKFZp686B04100 antibody
      • ISGF 3 antibody
      • ISGF3 antibody
      • OTTHUMP00000163552 antibody
      • OTTHUMP00000165046 antibody
      • OTTHUMP00000165047 antibody
      • OTTHUMP00000205845 antibody
      • Signal transducer and activator of transcription 1 antibody
      • Signal transducer and activator of transcription 1, 91kDa antibody
      • Signal transducer and activator of transcription 1-alpha/beta antibody
      • Stat1 antibody
      • STAT1_HUMAN antibody
      • STAT91 antibody
      • Transcription factor ISGF-3 components p91/p84 antibody
      see all

    Images

    • All lanes : Anti-STAT1 alpha antibody [EPYR2154] (HRP) (ab193891) at 1/5000 dilution

      Lane 1 : HeLa whole cell lysate (ab150035) at 10 µg
      Lane 2 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate at 10 µg
      Lane 3 : NIH 3T3 (Mouse embryonic fibroblast cell line) Whole Cell Lysate at 20 µg
      Lane 4 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate at 20 µg

      Developed using the ECL technique.

      Performed under reducing conditions.

      Predicted band size: 87 kDa
      Observed band size: 91 kDa (why is the actual band size different from the predicted?)


      Exposure time: 2 minutes


      This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab193891 overnight at 4°C. Antibody binding was visualised using ECL development solution ab133406.

    References

    ab193891 has not yet been referenced specifically in any publications.

    Customer reviews and Q&As

    There are currently no Customer reviews or Questions for ab193891.
    Please use the links above to contact us or submit feedback about this product.

    Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

    Sign up